Tharimmune Inc

NASDAQ:THARUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Contact Information

Headquarters

1200 Route 22 EastBRIDGEWATER, NJ, United States 08807

Phone

302-743-2995

Fax

302-645-1280

Executives

Chairman of the Board, President, Chief Executive Officer

Randy Milby

Chief Financial Officer

Thomas Hess

Chief Operating Officer, Director

Sireesh Appajosyula

Independent Director

Kelly Anderson

Independent Director

Lynne Bui